Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07245667 · ClinicalTrials.gov registry record · Phase 2
Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study
A Phase 2 study of Tinea Pedis, sponsored by Propedix.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 2
- Study locations
NCT07245667 is a Phase 2 study of Tinea Pedis that is actively recruiting participants, run by Propedix. The registered enrollment target is 150 participants, below the 310-participant average among 9 other Tinea Pedis trials with a reported enrollment target (52% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT07245667, a Phase 2 study of Tinea Pedis, is actively recruiting participants, sponsored by Propedix.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is designed to evaluate the safety and effectiveness of multiple 1% tolnaftate formulations delivered through novel stick-based vehicles in individuals with tinea pedis (athlete's foot).
Conditions Studied
Interventions
- DRUG 1% Tolnaftate Stick Formula A
- DRUG 1% Tolnaftate Stick Formula B
- DRUG 1% Tolnaftate Stick Formula C
Study Locations (2)
Massachusetts
- Kuchnir Dermatology and Dermatological Surgery - Framingham
- Kuchnir Dermatology and Dermatological Surgery - Milford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-12-30 |
| Est. Completion | 2026-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07245667
The ClinicalTrials.gov registry entry for NCT07245667 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 310-participant average among 9 other Tinea Pedis trials with a reported enrollment target (52% lower). The listed sponsor is Propedix, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tinea Pedis appearing as the primary indexed condition, and to 3 interventions - of which 1% Tolnaftate Stick Formula A is the first listed.
NCT07245667 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07245667 about?
NCT07245667 is a clinical study titled "Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study". This study is designed to evaluate the safety and effectiveness of multiple 1% tolnaftate formulations delivered through novel stick-based vehicles in individuals with tinea pedis (athlete's foot).
What is the current status of trial NCT07245667?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2024-12-30. Estimated completion is 2026-02.
What conditions does trial NCT07245667 study?
This clinical trial studies the following conditions: Tinea Pedis.
What interventions are being tested in trial NCT07245667?
The interventions under investigation include: 1% Tolnaftate Stick Formula A (DRUG), 1% Tolnaftate Stick Formula B (DRUG), 1% Tolnaftate Stick Formula C (DRUG).
Who is sponsoring clinical trial NCT07245667?
This trial is sponsored by Propedix, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07245667 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tinea Pedis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Econazole Foam 1% in Athlete's Foot
COMPLETED · Phase 2
-
Three-Arm Trial of Novel Treatment for Tinea Pedis
COMPLETED · Phase 2
-
Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis
COMPLETED · Phase 1
-
Spread of Dermatophytes Among Families
COMPLETED
-
BE Study of Naftifine HCL
COMPLETED · Phase 3
-
A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
COMPLETED · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.